This profile hasn't yet passed our validation checks
Submit your email to push it up the queue
Exosome Diagnostics, Inc.
Exosome Diagnostics, Inc., a leader in the field of liquid biopsy, is headquartered in the United States and operates across key regions globally. Founded in 2013, the company has made significant strides in the diagnostics industry, focusing on the development of innovative exosome-based technologies for cancer detection and monitoring. Exosome Diagnostics offers a range of unique products and services, including its proprietary exosome isolation and analysis platforms, which enable non-invasive testing with high sensitivity and specificity. The company has established a strong market position, recognised for its contributions to precision medicine and biomarker discovery. With a commitment to advancing diagnostic capabilities, Exosome Diagnostics continues to set benchmarks in the evolving landscape of molecular diagnostics.
DitchCarbon Score
How does Exosome Diagnostics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Exosome Diagnostics, Inc.'s score of 42 is higher than 68% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Exosome Diagnostics, Inc., headquartered in the US, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of Bio-Techne Corporation, which may influence its climate commitments and reporting practices. As part of its corporate family, Exosome Diagnostics inherits climate initiatives and targets from Bio-Techne Corporation. However, there are no specific reduction targets or significant achievements reported for Exosome Diagnostics at this time. The absence of documented emissions data suggests that the company may still be in the process of establishing its own climate strategy or reporting framework. In the broader context, Exosome Diagnostics is expected to align with industry standards and practices, potentially adopting initiatives such as the Science Based Targets initiative (SBTi) and other climate pledges as cascaded from Bio-Techne Corporation. This relationship may provide a pathway for future emissions reduction commitments and sustainability efforts.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | |
|---|---|---|---|
| Scope 1 | 2,684,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 12,694,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Exosome Diagnostics, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
